Atelerix

Executive Summary

Atelerix is a UK-based biotechnology company pioneering a hypothermic hydrogel technology for ambient temperature preservation and shipping of biological samples, including cells, tissues, and blood. Founded in 2013, the company's platform eliminates the need for cryopreservation or a cold chain, significantly reducing logistics costs and complexity while maintaining sample viability. This innovation addresses a critical bottleneck in the life sciences and cell therapy sectors, where reliable and affordable transport of living materials is essential. The technology is particularly relevant for research labs, clinical trials, and future therapeutic applications, offering a simple 'store-and-ship' solution that works at room temperature. As the company operates at a pre-clinical stage, its validating partnerships and pilot programs with academic and commercial entities will be key to advancing its platform toward broader adoption. By enabling seamless global distribution of biologics, Atelerix has the potential to transform supply chains in regenerative medicine, vaccine distribution, and diagnostic testing, making it a compelling player in the biosimilars and cell preservation landscape.

Upcoming Catalysts (preview)

• TBDStrategic Partnership with Cell Therapy or Logistics Company40% success
• Q4 2026Product Launch or Pilot Program Expansion35% success
• Q3 2026Grant or Non-Dilutive Funding for R&D50% success